Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Chromosome 1 amplification has similar prognostic value to del(17p13) and t(4;14)(p16;q32) in multiple myeloma patients: analysis of real-life data from the Polish Myeloma Study Group

N. Grzasko, R. Hajek, M. Hus, S. Chocholska, M. Morawska, K. Giannopoulos, K. Czarnocki, A. Druzd-Sitek, B. Pienkowska-Grela, J. Rygier, L. Usnarska-Zubkiewicz, D. Dytfeld, T. Kubicki, A. Jurczyszyn, M. Korpysz, A. Dmoszynska,

. 2017 ; 58 (9) : 1-15. [pub] 20170116

Language English Country England, Great Britain

Document type Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc18025193

The study aimed to assess prognostic significance of del(13q14), del(17p13), t(4;14)(p16;q32), and amp(1q21) in newly diagnosed myeloma patients treated mostly with thalidomide-based therapies. All genetic abnormalities except del(13q14) were independent prognostic factors associated with shortened progression-free survival (PFS) and overall survival (OS). Patients with no abnormalities, one abnormality, and ≥2 abnormalities had a median PFS of 41.8, 17.0, and 10.0 months, respectively; a median OS was not reached, 48.0 and 23.3 months, respectively. According to the presence of amp(1q21), t(4;14)(p16;q32), and del(17p13) and the International Staging System (ISS), we stratified patients into low-risk, intermediate-risk and high-risk groups. A median PFS was 52.9, 25.6, and 10.0 months, respectively; a median OS was not reached, 64.0 and 25.0 months, respectively. In conclusion, our study confirmed the prognostic value of cytogenetic changes and showed that prognostic models based on ISS and cytogenetic studies should include not only del(17p13) and t(4;14)(p16;q32), but also amp(1q21).

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18025193
003      
CZ-PrNML
005      
20180717091454.0
007      
ta
008      
180709s2017 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1080/10428194.2016.1272684 $2 doi
035    __
$a (PubMed)28092996
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Grzasko, Norbert $u a Department of Hematology , St. John's Cancer Center , Lublin , Poland. b Department of Experimental Hematooncology , Medical University of Lublin , Lublin , Poland.
245    10
$a Chromosome 1 amplification has similar prognostic value to del(17p13) and t(4;14)(p16;q32) in multiple myeloma patients: analysis of real-life data from the Polish Myeloma Study Group / $c N. Grzasko, R. Hajek, M. Hus, S. Chocholska, M. Morawska, K. Giannopoulos, K. Czarnocki, A. Druzd-Sitek, B. Pienkowska-Grela, J. Rygier, L. Usnarska-Zubkiewicz, D. Dytfeld, T. Kubicki, A. Jurczyszyn, M. Korpysz, A. Dmoszynska,
520    9_
$a The study aimed to assess prognostic significance of del(13q14), del(17p13), t(4;14)(p16;q32), and amp(1q21) in newly diagnosed myeloma patients treated mostly with thalidomide-based therapies. All genetic abnormalities except del(13q14) were independent prognostic factors associated with shortened progression-free survival (PFS) and overall survival (OS). Patients with no abnormalities, one abnormality, and ≥2 abnormalities had a median PFS of 41.8, 17.0, and 10.0 months, respectively; a median OS was not reached, 48.0 and 23.3 months, respectively. According to the presence of amp(1q21), t(4;14)(p16;q32), and del(17p13) and the International Staging System (ISS), we stratified patients into low-risk, intermediate-risk and high-risk groups. A median PFS was 52.9, 25.6, and 10.0 months, respectively; a median OS was not reached, 64.0 and 25.0 months, respectively. In conclusion, our study confirmed the prognostic value of cytogenetic changes and showed that prognostic models based on ISS and cytogenetic studies should include not only del(17p13) and t(4;14)(p16;q32), but also amp(1q21).
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    12
$a chromozomální delece $7 D002872
650    12
$a duplikace chromozomů $7 D058674
650    _2
$a lidské chromozomy, pár 1 $7 D002878
650    _2
$a lidské chromozomy, pár 14 $7 D002883
650    _2
$a lidské chromozomy, pár 17 $7 D002886
650    _2
$a lidské chromozomy, pár 4 $7 D002894
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a hybridizace in situ fluorescenční $7 D017404
650    _2
$a incidence $7 D015994
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a mnohočetný myelom $x epidemiologie $x genetika $x mortalita $7 D009101
650    _2
$a Polsko $x epidemiologie $7 D011044
650    _2
$a prognóza $7 D011379
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a analýza přežití $7 D016019
650    12
$a translokace genetická $7 D014178
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Hajek, Roman $u c University Hospital Ostrava and Faculty of Medicine, University of Ostrava , Ostrava , Czech Republic.
700    1_
$a Hus, Marek $u b Department of Experimental Hematooncology , Medical University of Lublin , Lublin , Poland.
700    1_
$a Chocholska, Sylwia $u b Department of Experimental Hematooncology , Medical University of Lublin , Lublin , Poland.
700    1_
$a Morawska, Marta $u a Department of Hematology , St. John's Cancer Center , Lublin , Poland.
700    1_
$a Giannopoulos, Krzysztof $u a Department of Hematology , St. John's Cancer Center , Lublin , Poland. b Department of Experimental Hematooncology , Medical University of Lublin , Lublin , Poland.
700    1_
$a Czarnocki, Krzysztof $u a Department of Hematology , St. John's Cancer Center , Lublin , Poland. d Department of Ergonomics, Faculty of Management, Lublin University of Technology , Lublin , Poland.
700    1_
$a Druzd-Sitek, Agnieszka $u e Department of Lymphoproliferative Diseases , Maria Sklodowska-Curie Memorial Institute and Oncology Centre , Warsaw , Poland.
700    1_
$a Pienkowska-Grela, Barbara $u e Department of Lymphoproliferative Diseases , Maria Sklodowska-Curie Memorial Institute and Oncology Centre , Warsaw , Poland.
700    1_
$a Rygier, Jolanta $u e Department of Lymphoproliferative Diseases , Maria Sklodowska-Curie Memorial Institute and Oncology Centre , Warsaw , Poland.
700    1_
$a Usnarska-Zubkiewicz, Lidia $u f Department of Hematology, Blood Neoplasms and Bone Marrow Transplantation , Wroclaw Medical University , Wroclaw , Poland.
700    1_
$a Dytfeld, Dominik $u g Department of Hematology and Bone Marrow Transplantation Poznan , Poznan University of Medical Sciences , Poland.
700    1_
$a Kubicki, Tadeusz $u g Department of Hematology and Bone Marrow Transplantation Poznan , Poznan University of Medical Sciences , Poland.
700    1_
$a Jurczyszyn, Artur $u h Department of Hematology , Jagiellonian University Medical College , Cracow , Poland.
700    1_
$a Korpysz, Maciej $u i Department of Biochemical Diagnostics , Medical University of Lublin , Lublin , Poland.
700    1_
$a Dmoszynska, Anna $u j Polish Myeloma Study Group , Lublin , Poland.
773    0_
$w MED00003140 $t Leukemia & lymphoma $x 1029-2403 $g Roč. 58, č. 9 (2017), s. 1-15
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28092996 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180709 $b ABA008
991    __
$a 20180717091753 $b ABA008
999    __
$a ok $b bmc $g 1317324 $s 1022114
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 58 $c 9 $d 1-15 $e 20170116 $i 1029-2403 $m Leukemia & lymphoma $n Leuk Lymphoma $x MED00003140
LZP    __
$a Pubmed-20180709

Find record

Citation metrics

Archiving options